NCT05627466No Longer Available不适用
Expanded Access Program for Magrolimab
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The goal of this expanded access program is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory acute myeloid leukemia (AML).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals with confirmation of acute myeloid leukemia (AML) according to WHO 2016 classification who are refractory or relapsed, ineligible for all known drugs with proven efficacy, and ineligible for existing clinical studies; and the treating physician has assessed that the potential benefits of magrolimab outweigh the risks.
- •Eastern Cooperative Oncology Group performance status score of 0 to
- •Treating physician plans to administer magrolimab in combination with azacitadine/venetoclax or magrolimab in combination with azacitadine alone, following the indication-specific combinations described in the protocol.
排除标准
- •Known hypersensitivity to magrolimab, azacitidine, venetoclax, their metabolites, or formulation excipients, if applicable to planned treatment regimen.
- •Prior treatment with cluster of differentiation (CD)47 or signal regulatory protein alpha (SIRPα)-targeting agents.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究者
相似试验
No Longer Available
不适用
Expanded Access for MarizomibSolid TumorNCT04644107Celgene
Approved For Marketing
不适用
Margetuximab Expanded Access ProgramNCT03133988TerSera Therapeutics LLC
No Longer Available
不适用
Expanded Access to EpcoritamabLymphomaNCT05692050AbbVie
No Longer Available
不适用
Expanded Access for RelatlimabNCT05170659Bristol-Myers Squibb
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie